INCY Incyte Genomics Inc Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
11:42
Jun 08
AlphaSense AI market intelligence platform
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its hematology portfolio into bleeding disorders.
INCY
01:10
Mar 08
@seekingalpha
The failure to win a key FDA label expansion is a direct negative catalyst for the stock, impacting future revenue streams.
INCY
MED
08:24
Feb 20
@seekingalpha
The trade is long Incyte based on the continued strength of its ruxolitinib franchise and strong expected sales growth for its drug Opzelura.
INCY
MED

About INCY Analyst Coverage

Buzzberg tracks INCY (Incyte Genomics Inc) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked.